We are live on ! Find out more
CPX

Canaan Partners XI Portfolio holdings

AUM $127M
1-Year Est. Return 217.49%
This Fund
S&P 500
This Quarter Est. Return
+348.64%
1 Year Est. Return
+217.49%
3 Year Est. Return
+1,311.52%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$172M
AUM Growth
+$105M
Cap. Flow
-$6.81M
Cap. Flow %
-3.97%
Top 10 Hldgs %
100%
Holding
4
New
–
Increased
–
Reduced
3
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
TYRA icon
Tyra Biosciences
TYRA
+$5.1M
2
AEVA
Aeva Technologies
AEVA
+$1.52M
3
RLYB icon
Rallybio
RLYB
+$196K

Sector Composition

Rank Sector Weight
1 Technology 79.71%
2 Healthcare 20.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AEVA
1
Aeva Technologies
AEVA
$1.02B
$136M 79.14%
3,597,039
-100,000
-3% -$1.52M
TYRA icon
2
Tyra Biosciences
TYRA
$1.82B
$34.5M 20.1%
3,608,109
-536,481
-13% -$5.1M
UPBD icon
3
Upbound Group
UPBD
$1.19B
$974K 0.57%
38,824
– –
RLYB icon
4
Rallybio
RLYB
$86.6M
$318K 0.19%
117,623
-73,946
-39% -$196K

Similar funds

ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM
CF
Concorde Financial Dallas, Texas $127M AUM 24.97% 1-Year Est. Return
MF
Midwestern Financial Iowa City, Iowa $127M AUM 13.96% 1-Year Est. Return
SAP
Strategic Advisory Partners Greensboro, North Carolina $127M AUM
S
Storgate Dallas, Texas $127M AUM
PIP
PB Investment Partners Burlingame, California $127M AUM 0.83% 1-Year Est. Return
VDC
Van Diest Capital Poly City, Iowa $127M AUM
PA
Persium Advisors Atlanta, Georgia $127M AUM 18.78% 1-Year Est. Return

Canaan Partners XI's Q2 2025 Portfolio in Review

As of Q2 2025, Canaan Partners XI held 4 positions worth $172M, up 159% from $66.4M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Canaan Partners XI withdrew a net $6.81M in Q2 2025, reducing 3 holdings. Its largest reduction was Tyra Biosciences, cutting an estimated $5.1M.

By sector, the portfolio is most concentrated in Technology at 80% of assets, up from 40% a quarter earlier, followed by Healthcare.

  • Canaan Partners XI's biggest Q2 2025 reduction was Tyra Biosciences, cutting an estimated $5.1M.
  • Canaan Partners XI's ten largest holdings make up 100% of its $172M portfolio in Q2 2025.
  • Canaan Partners XI opened 0 new positions and closed 0 in Q2 2025.
  • Canaan Partners XI's portfolio value rose 159% quarter-over-quarter to $172M.

Based on Canaan Partners XI's 13F filing for Q2 2025, filed 17 Jul 2025.